A carregar...
The PPARγ Agonist Efatutazone Increases the Spectrum of Well-Differentiated Mammary Cancer Subtypes Initiated by Loss of Full-Length BRCA1 in Association with TP53 Haploinsufficiency
Peroxisome proliferator–activated receptor gamma (PPARγ) agonists have anticancer activity and influence cell differentiation. We examined the impact of the selective PPARγ agonist efatutazone on mammary cancer pathogenesis in a mouse model of BRCA1 mutation. Mice with conditional loss of full-lengt...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Investigative Pathology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3668033/ https://ncbi.nlm.nih.gov/pubmed/23664366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajpath.2013.02.006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|